home / stock / ocup / ocup news

OCUP News and Press, Ocuphire Pharma Inc Com

Stock Information
Company Name: Ocuphire Pharma Inc Com
Stock Symbol: OCUP
Market: NASDAQ
Website: ocuphire.com
Menu
OCUP OCUP Quote OCUP Short OCUP News OCUP Articles OCUP Message Board
Get OCUP Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUP - Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today anno...
OCUP - Ocuphire Pharma GAAP EPS of -$0.29 misses by $0.20, revenue of $1.71M misses by $2.96M

2024-05-10 08:05:37 ET More on Ocuphire Pharma Seeking Alpha’s Quant Rating on Ocuphire Pharma Historical earnings data for Ocuphire Pharma Financial information for Ocuphire Pharma Read the full article on Seeking Alpha For further details see...

OCUP - Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial r...

OCUP - Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data...
OCUP - Ocuphire Pharma to Present at the Aegis Virtual Conference

FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief...

OCUP - Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, ...

OCUP - First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for t...
OCUP - Ocuphire Announces the U.S. Commercial Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. comme...

OCUP - OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023

2024-03-15 11:53:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (NASDAQ: OCUP ) just reported results for the fourth quarter of 2023. Ocuphire Pharma reported earnings per share of -21 cents. This was below the analyst ...

OCUP - Ocuphire Pharma GAAP EPS of -$0.21 misses by $0.21, revenue of $1.69M misses by $4.27M

2024-03-08 08:25:26 ET More on Ocuphire Pharma Seeking Alpha’s Quant Rating on Ocuphire Pharma Historical earnings data for Ocuphire Pharma Financial information for Ocuphire Pharma Read the full article on Seeking Alpha For further details see...
Next 10